Achieve Life Sciences reports Q3 EPS (34c), consensus (38c)

As of September 30 the company’s cash, cash equivalents, and restricted cash was $20M . Total operating expenses for the three and nine months ended September 30, 2023 were $6.6 million and $22.9 million, respectively. Total net loss for the three and nine months ended September 30, 2023 was $7.1 M and $24.3M respectively. As of November 9, 2023, Achieve had 21,165,760 shares outstanding.”This has been a pivotal year for Achieve and we made significant strides to continue our progress on advancing cytisinicline throughout the third quarter,” said John Bencich, CEO of Achieve. “Our primary focus remains on fulfilling FDA requirements to enable the submission of a New Drug Application for cytisinicline and engaging with partners who align with our vision for the substantial public health benefits of cytisinicline.”